CML CP, dasatinib 1L or 2L ≥ 2 years, confirmed MR 4.5 ≥ 1 year, 1‐log reduction or < 10% of BCR::ABL1 at 3 m of dasatinibf. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.